1 / 5

Lenalidomide Nonclinical Overview

Lenalidomide Nonclinical Overview. Dr. David Stirling Chief Scientific Officer Celgene Corporation. Lenalidomide Nonclinical Pharmacokinetic Studies. Rapidly absorbed Extensive distribution into tissues Low protein binding Does not inhibit or induce major cytochrome P450 isozymes

jacqui
Télécharger la présentation

Lenalidomide Nonclinical Overview

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Lenalidomide Nonclinical Overview Dr. David Stirling Chief Scientific Officer Celgene Corporation

  2. Lenalidomide Nonclinical Pharmacokinetic Studies • Rapidly absorbed • Extensive distribution into tissues • Low protein binding • Does not inhibit or induce major cytochrome P450 isozymes • Partial metabolism related to hydrolysis observed in vivo • Rapidly excreted via the urine mainly as unchanged drug

  3. Lenalidomide vs Thalidomide • Lenalidomide and thalidomide are pharmacologically different drugs based on • Chemistry/metabolism • Structurally linked • No common breakdown products • Cellular biology • Significant potency differences • Molecular biology • Del 5q sensitivity • Clinical profile • Different safety profiles • Non-clinical reproductive/development toxicology • Lenalidomide is not selectively toxic to development • Lenalidomide did not produce limb malformations

  4. Reproductive and Developmental ToxicityAdditional Studies in Rabbits • Pulse dosing study completed • High dose on GDs 8 through 10 • No malformations • Additional Seg II studies in progress • Dose-ranging study with TK completed • Developmental toxicity study completed • Analysis and report preparation underway

  5. Lenalidomide: Cellular Mechanism • Anti-proliferative (proapoptotic, cell cycle arrest) • Proerythropoietic (stimulate HbF synthesis) • Cytokine regulation (TNFα, IL-10, IL-2, IFN-γ) • Immune stimulation (T cells, NK cells) • Anti-angiogenic • Expand progenitor cell populations

More Related